XERS · Xeris Biopharma Holdings, Inc.
$8.60
+0.27 (+3.24%)
At close · Aug 14
Market Cap
$1.57B
Shares
182.32M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.60
Open$8.33
Day$8.25–8.67
52W close$5.29–9.90
Avg vol 30d1.8M
Short int9.2M · 5.1% float · 6.8d
Short vol45%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+10%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
72%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+31%
trailing
YTD return
+10%
this year
Relative strength
+17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.06% of float · ▼ -8.5% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
234 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+143%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$27.5M
Balance sheet
$109.3M
net debt
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Total revenue
· full-year 2026
$385M – $390M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Total revenue
· full year 2025
$285M – $290M
Guided vs delivered
· last 1 settled
Total revenue
full year 2024
guided $170M – $200M
$203.07M
Beat +9.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
72%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.06% of float · ▼ -8.5% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
234 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $9 · 72%
Range high $10
vs 200-day avg +22%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $34.4M | six months ended June 30, 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XERS
this stock
Xeris Biopharma Holdings, Inc.
|
$1.57B | +9.6% | +142.7% | — | 5.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.59B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XERS | +8.5% | -2.3% | +30.7% | +6.4% | +9.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +8.1% | -6.7% | +16.9% | +2.5% | -4.3% |
Key facts
CIK
1867096
CUSIP
98422E103
13F (30d)
231 filings
226 filers
Visit website
Investor relations